More on pregnancy and #APS, now from obstetric perspective.
Only 1% of recurrent miscarriage patients had APS antibodies, similar to controls.
#ISTH2025
Implementation matters!
A guideline-driven VTE prevention program (Vermont Model) led to ~60% of high-risk cancer patients receiving prophylactic anticoagulation—resulting in a 60% reduction in VTE and 56% reduction in death. #ISTH2025 #VTEprevention 🩸
@marycushmanmd.bsky.social
Marc Rodger highlighting the #Highlow study and providing guidance on how to implement the results 👌🏼
It took 7 years to recruit 51 patients for the IMPACT single-arm study on certiluzomab on top of LMWH-aspirin shows adverse outcome in 20% which is lower than non-contemporary controls.
#ISTH2025
Now my favourite topic presented eloquently by prof Marc Rodger.
Answering all the questions needed for providing well-informed information to your patients.
Put the #LMWH needles away in patients with placenta-mediated complications in inherited #thrombophilia!
#AFFIRM #ALIFE2
#ISTH2025
What an inspiring #ISTH2025!
It was wonderful to host the global #thrombosis & #hemostasis community in DC.
From the latest science & innovations to networking & building new collabs - it had it all!
Look out for recordings & other post- @isth.org congress updates.
Goodbye & see you @ #ISTH2026!
📰 Check it out! The @ash.hematology.org and ISTH Updated Guidelines on the Treatment of Pediatric VTE are featured in Hematology Advisor.
Don’t miss this spotlight on our collaborative effort!
📖 Read the full feature: www.hematologyadvisor.com/news/pediatr...
#PediatricVTE #Hematology #ISTH
Why do we have so little data on pregnancy and thrombotic outcomes in #APS??
Well-illustrated by State-of-the-Art lecture by dr Karen Breen.
We MUST do better!
#ISTH2025
Congratulations to @isth.org Councilor @middeldorps.bsky.social on being named & delivering the 2025 Sol Sherry Disting. Lecture in Thrombosis @ the recent @americanheart.bsky.social Scientific Sessions recognizing her role as a foremost clinician & researcher in the field of CV disease & stroke!
The ASH and ISTH updated guidelines for treatment of pediatric venous thromboembolism, focusing on improved outcomes and patient quality of life.
